List of bibliographic references
Number of relevant bibliographic references: 9.
| Ident. | Authors (with country if any) | Title |
|---|
| 000222 (2017) |
Miguel Martin [Espagne] ; Frankie A. Holmes [États-Unis] ; Bent Ejlertsen [Danemark] ; Suzette Delaloge [France] ; Beverly Moy [États-Unis] ; Hiroji Iwata [Japon] ; Gunter Von Minckwitz [Allemagne] ; Stephen K L. Chia [Canada] ; Janine Mansi [Royaume-Uni] ; Carlos H. Barrios [Brésil] ; Michael Gnant [Autriche] ; Zorica Tomaševi [Serbie] ; Neelima Denduluri [États-Unis] ; Robert Šeparovi [Croatie] ; Erhan Gokmen [Turquie] ; Anna Bashford [Nouvelle-Zélande] ; Manuel Ruiz Borrego [Espagne] ; Sung-Bae Kim [Corée du Sud] ; Erik Hugger Jakobsen [Danemark] ; Audrone Ciceniene [Lituanie] ; Kenichi Inoue [Japon] ; Friedrich Overkamp [Allemagne] ; Joan B. Heijns [Pays-Bas] ; Anne C. Armstrong [Royaume-Uni] ; John S. Link [États-Unis] ; Anil Abraham Joy [Canada] ; Richard Bryce [États-Unis] ; Alvin Wong [États-Unis] ; Susan Moran [États-Unis] ; Bin Yao [États-Unis] ; Feng Xu [États-Unis] ; Alan Auerbach [États-Unis] ; Marc Buyse [Belgique] ; Arlene Chan [Australie] | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000223 (2017) |
Sibylle Loibl [Allemagne] ; Lorena De La Pena [Espagne] ; Valentina Nekljudova [Allemagne] ; Dimitrios Zardavas [Belgique] ; Stefan Michiels [France] ; Carsten Denkert [Allemagne] ; Mahdi Rezai [Allemagne] ; Bego A Bermejo [Espagne] ; Michael Untch [Allemagne] ; Soo Chin Lee [Singapour] ; Sabine Turri [France] ; Patrick Urban [Suisse] ; Sherko Kümmel [Allemagne] ; Guenther Steger [Autriche] ; Andrea Gombos [Belgique] ; Michael Lux [Allemagne] ; Martine J. Piccart [Belgique] ; Gunter Von Minckwitz [Allemagne] ; José Baselga [États-Unis] ; Sherene Loi [Australie] | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). |
| 000663 (2016) |
Carsten Denkert [Allemagne] ; Stephan Wienert [Allemagne] ; Audrey Poterie [France] ; Sibylle Loibl [Allemagne] ; Jan Budczies [Allemagne] ; Sunil Badve [États-Unis] ; Zsuzsanna Bago-Horvath [Autriche] ; Anita Bane [Canada] ; Shahinaz Bedri [Qatar] ; Jane Brock [États-Unis] ; Ewa Chmielik [Pologne] ; Matthias Christgen [Allemagne] ; Cecile Colpaert [Belgique] ; Sandra Demaria [États-Unis] ; Gert Van Den Eynden [Belgique] ; Giuseppe Floris [Belgique] ; Stephen B. Fox [Australie] ; Dongxia Gao [Canada] ; Barbara Ingold Heppner [Allemagne] ; S Rim Kim [États-Unis] ; Zuzana Kos [Canada] ; Hans H. Kreipe [Allemagne] ; Sunil R. Lakhani [Australie] ; Frederique Penault-Llorca [France] ; Giancarlo Pruneri [Italie] ; Nina Radosevic-Robin [France] ; David L. Rimm [États-Unis] ; Stuart J. Schnitt [États-Unis] ; Bruno V. Sinn [Allemagne] ; Peter Sinn [Allemagne] ; Nicolas Sirtaine [Belgique] ; Sandra A. O'Toole [Australie] ; Giuseppe Viale [Italie] ; Koen Van De Vijver [Pays-Bas] ; Roland De Wind [Belgique] ; Gunter Von Minckwitz [Allemagne] ; Frederick Klauschen [Allemagne] ; Michael Untch [Allemagne] ; Peter A. Fasching [Allemagne] ; Toralf Reimer [Allemagne] ; Karen Willard-Gallo [Belgique] ; Stefan Michiels [France] ; Sherene Loi [Australie] ; Roberto Salgado [Belgique] | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. |
| 000770 (2016) |
Arlene Chan [Australie] ; Suzette Delaloge [France] ; Frankie A. Holmes [États-Unis] ; Beverly Moy [États-Unis] ; Hiroji Iwata [Japon] ; Vernon J. Harvey [Nouvelle-Zélande] ; Nicholas J. Robert [États-Unis] ; Tajana Silovski [Croatie] ; Erhan Gokmen [Turquie] ; Gunter Von Minckwitz [Allemagne] ; Bent Ejlertsen [Danemark] ; Stephen K L. Chia [Canada] ; Janine Mansi [Royaume-Uni] ; Carlos H. Barrios [Brésil] ; Michael Gnant [Autriche] ; Marc Buyse [Belgique] ; Ira Gore [États-Unis] ; John Smith [États-Unis] ; Graydon Harker [États-Unis] ; Norikazu Masuda [Japon] ; Katarina Petrakova [République tchèque] ; Angel Guerrero Zotano [Espagne] ; Nicholas Iannotti [États-Unis] ; Gladys Rodriguez [États-Unis] ; Pierfrancesco Tassone [Italie] ; Alvin Wong [États-Unis] ; Richard Bryce [États-Unis] ; Yining Ye [États-Unis] ; Bin Yao [États-Unis] ; Miguel Martin [Espagne] | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000A29 (2016) |
John F. Forbes [Australie] ; Ivana Sestak [Royaume-Uni] ; Anthony Howell [Royaume-Uni] ; Bernardo Bonanni [Italie] ; Nigel Bundred [Royaume-Uni] ; Christelle Levy [France] ; Gunter Von Minckwitz [Allemagne] ; Wolfgang Eiermann [Allemagne] ; Patrick Neven [Belgique] ; Michael Stierer [Autriche] ; Chris Holcombe [Royaume-Uni] ; Robert E. Coleman [Royaume-Uni] ; Louise Jones [Royaume-Uni] ; Ian Ellis [Royaume-Uni] ; Jack Cuzick [Royaume-Uni] | Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial |
| 001764 (2012) |
Masakazu Toi [Japon] ; John R. Benson [Royaume-Uni] ; Eric P. Winer [États-Unis] ; John F. Forbes [Australie] ; Gunter Von Minckwitz [Allemagne] ; Mehra Golshan [États-Unis] ; John F. R. Robertson [Royaume-Uni] ; Hironobu Sasano [Japon] ; Bernard F. Cole [États-Unis] ; Louis W. C. Chow [Hong Kong] ; Mark D. Pegram [États-Unis] ; Wonshik Han [Corée du Sud] ; Chiun-Sheng Huang [Taïwan] ; Tadashi Ikeda [Japon] ; Shotaro Kanao [Japon] ; Eun-Sook Lee [Corée du Sud] ; Shinzaburo Noguchi [Japon] ; Shinji Ohno [Japon] ; Ann H. Partridge [États-Unis] ; Roman Rouzier [France] ; Mitsuhiro Tozaki [Japon] ; Tomoharu Sugie [Japon] ; Akira Yamauchi [Japon] ; Takashi Inamoto [Japon] | Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference |
| 001B27 (2011) |
Vicente Valero [États-Unis, Australie, Pologne, Allemagne, France] ; John Forbes ; Mark D. Pegram ; Tadeusz Pienkowski ; Wolfgang Eiermann ; Gunter Von Minckwitz ; Henri Roche ; Miguel Martin ; John Crown ; John R. Mackey ; Pierre Fumoleau ; Janusz Rolski ; Zrinka Mrsic-Krmpotic ; Agnieszka Jagiello-Gruszfeld ; Alessandro Riva ; Marc Buyse ; Henry Taupin ; Guido Sauter ; Michael F. Press ; Dennis J. Slamon | Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens |
| 001C21 (2011) |
Dennis Slamon [États-Unis] ; Wolfgang Eiermann [Allemagne] ; Nicholas Robert [États-Unis] ; Tadeusz Pienkowski [Pologne] ; Miguel Martin [Espagne] ; Michael Press [États-Unis] ; John Mackey [Canada] ; John Glaspy [États-Unis] ; Arlene Chan [Australie] ; Marek Pawlicki [États-Unis] ; Tamas Pinter [Hongrie] ; Vicente Valero [États-Unis] ; Mei-Ching Liu [Taïwan] ; Guido Sauter [Allemagne] ; Gunter Von Minckwitz [Allemagne] ; Frances Visco [États-Unis] ; Valerie Bee [France] ; Marc Buyse [Belgique] ; Belguendouz Bendahmane [France] ; Isabelle Tabah-Fisch [France] ; Mary-Ann Lindsay [France] ; Alessandro Riva [France] ; John Crown [Israël] | Adjuvant Trastuzumab in HER2-Positive Breast Cancer |
| 002235 (2008) |
Nigel J. Bundred [Royaume-Uni] ; Ian D. Campbell [Nouvelle-Zélande] ; Neville Davidson [Royaume-Uni] ; Richard H. Deboer [Australie] ; Holger Eidtmann [Allemagne] ; Alain Monnier [France] ; Patrick Neven [Belgique] ; Gunter Von Minckwitz [Allemagne] ; Joel C. Miller [États-Unis] ; Nora L. Schenk [États-Unis] ; Robert E. Coleman [Royaume-Uni] | Effective Inhibition of Aromatase Inhibitor-associated Bone Loss by Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole : ZO-FAST Study Results |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Breast cancer |
| 4 | Female |
| 3 | Adult |
| 3 | Antineoplastic agent |
| 3 | Double-Blind Method |
| 3 | Humans |
| 3 | Middle Aged |
| 2 | Aged |
| 2 | Breast Neoplasms (drug therapy) |
| 2 | Breast Neoplasms (pathology) |
| 2 | Breast Neoplasms (surgery) |
| 2 | Cancerology |
| 2 | Chemotherapy, Adjuvant |
| 2 | Early |
| 2 | Human |
| 2 | Mammary gland |
| 2 | Postmenopause |
| 2 | Receptor, ErbB-2 (metabolism) |
| 2 | Trastuzumab |
| 2 | Trastuzumab (administration & dosage) |
| 2 | Trastuzumab (adverse effects) |
| 2 | Treatment Outcome |
| 2 | erbB2 Gene |
| 1 | Adjuvant |
| 1 | Administration, Oral |
| 1 | Advanced stage |
| 1 | Aminopyridines (administration & dosage) |
| 1 | Aminopyridines (adverse effects) |
| 1 | Antineoplastic Agents, Hormonal (administration & dosage) |
| 1 | Antineoplastic Agents, Hormonal (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Antiresorptive agent |
| 1 | Aromatase Inhibitors (administration & dosage) |
| 1 | Aromatase Inhibitors (adverse effects) |
| 1 | Aromatase Inhibitors (therapeutic use) |
| 1 | Australia |
| 1 | Biomarkers, Tumor (antagonists & inhibitors) |
| 1 | Biomarkers, Tumor (genetics) |
| 1 | Biomarkers, Tumor (metabolism) |
| 1 | Biopsy |
| 1 | Bone mineral density |
| 1 | Breast |
| 1 | Breast Neoplasms (enzymology) |
| 1 | Breast Neoplasms (mortality) |
| 1 | Breast Neoplasms (prevention & control) |
| 1 | C-Onc gene |
| 1 | Carboplatin |
| 1 | Carcinoma, Ductal, Breast (prevention & control) |
| 1 | Chemical and Drug Induced Liver Injury (etiology) |
| 1 | Chemotherapy |
| 1 | Class I Phosphatidylinositol 3-Kinases (antagonists & inhibitors) |
| 1 | Class I Phosphatidylinositol 3-Kinases (genetics) |
| 1 | Class I Phosphatidylinositol 3-Kinases (metabolism) |
| 1 | Clinical management |
| 1 | Comparative study |
| 1 | Consensus conference |
| 1 | Disease-Free Survival |
| 1 | Docetaxel |
| 1 | Dose-Response Relationship, Drug |
| 1 | Drug Administration Schedule |
| 1 | Early Termination of Clinical Trials |
| 1 | Efficiency |
| 1 | Estrogen synthase |
| 1 | Europe |
| 1 | First line treatment |
| 1 | Follow-Up Studies |
| 1 | Gene amplification |
| 1 | Human Epidermal growth factor Receptor 2 |
| 1 | Immunomodulator |
| 1 | Intention to Treat Analysis |
| 1 | Internationality |
| 1 | Kaplan-Meier Estimate |
| 1 | Ki-67 Antigen (metabolism) |
| 1 | Letrozole |
| 1 | Lymphocytes, Tumor-Infiltrating (drug effects) |
| 1 | Malignant tumor |
| 1 | Management |
| 1 | Mastectomy (methods) |
| 1 | Medicine |
| 1 | Metastasis |
| 1 | Monoclonal antibody |
| 1 | Morpholines (administration & dosage) |
| 1 | Morpholines (adverse effects) |
| 1 | Multicenter study |
| 1 | Mutation |
| 1 | Neoadjuvant Therapy (adverse effects) |
| 1 | Neoplasm Invasiveness (pathology) |
| 1 | Neoplasm Recurrence, Local (prevention & control) |
| 1 | Neoplasm Staging |
| 1 | Nitriles (administration & dosage) |
| 1 | Nitriles (adverse effects) |
| 1 | Nitriles (therapeutic use) |
| 1 | Osteopenia |
| 1 | Paclitaxel (administration & dosage) |
| 1 | Paclitaxel (adverse effects) |
| 1 | Phase III trial |
| 1 | Preoperative |
| 1 | Proportional Hazards Models |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Gunter Von Minckwitz"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Gunter Von Minckwitz" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Gunter Von Minckwitz
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
